MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Illumina Inc

Slēgts

SektorsVeselības aprūpe

77.58 2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

75

Max

78.05

Galvenie mērījumi

By Trading Economics

Ienākumi

187M

Pārdošana

24M

1.1B

EPS

0.86

Peļņas marža

16.938

Darbinieki

8,970

EBITDA

54M

283M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+48.81% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-10B

11B

Iepriekšējā atvēršanas cena

75.58

Iepriekšējā slēgšanas cena

77.58

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Illumina Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. marts 09:18 UTC

Karstas akcijas

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

2025. g. 10. marts 21:07 UTC

Top Ziņas

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

2025. g. 10. marts 20:01 UTC

Top Ziņas

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

2025. g. 4. marts 10:56 UTC

Karstas akcijas

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Salīdzinājums

Cenas izmaiņa

Illumina Inc Prognoze

Cenas mērķis

By TipRanks

48.81% augšup

Prognoze 12 mēnešiem

Vidējais 113.47 USD  48.81%

Augstākais 160 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Illumina Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

9

Pirkt

8

Turēt

2

Pārdot

Tehniskais rādītājs

By Trading Central

75.05 / 76.3Atbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.